Devergie’s disease: what’s new? Review article

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

This literature review analyzed published articles that provide information about the etiology and patho- genesis of Devergie’s disease. This paper also presents the current classification and systematization of modern methods of pharmacotherapy. In this review, treatment issues were identified, which highlights the need for further clinical studies of Devergie’s disease.

Full Text

Restricted Access

About the authors

N. P. Teplyuk

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: purim91@mail.ru
ORCID iD: 0000-0002-3910-5710
Russian Federation, Moscow

N. L. Shimanovskiy

N.I. Pirogov Russian Research Medical University

Email: purim91@mail.ru
ORCID iD: 0000-0001-6927-7727
Russian Federation, Moscow

P. M. Ruvinova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Author for correspondence.
Email: purim91@mail.ru
ORCID iD: 0000-0002-3910-5710

аспирант

Russian Federation, Moscow

References

  1. Tarral C. General psoriasis-desquamation from the parts covered by hair. In: Rayer P, ed. A theoretical and practical treatise on the diseases of the skin. London: Printed for JB Baillere; 1835.
  2. Besnier E. Observation pour server a historic clinique du, pityriasis rubra pilaris. Am Dermatol Syphil. (Paris) 1889;10:253-87.
  3. Griffiths WA. Pityriasis rubra pilaris. Clin Exp Dermatol. 1980;5(1):105-12.
  4. Sehgal VN, Jain MK, Mathur RP. Pityriasisrubra pilarisin Indians. Br J Dermatol. 1989;121(6):821-2.
  5. Piamphongsant T, Akaraphant R. Pityriasis rubra pilaris: a new proposed classification. Clin Exp Dermatol. 1994;19(2):134-8.
  6. Griffiths WA. Vitamin A and pityriasis rubra pilaris. J Am Acad Dermatol. 1982;7(4):555.
  7. Wang D, Chong V, Chong WS, Oon HH. A review on pityriasis rubra pilaris. Am J Clin Dermatol. 2018;19(3):377-90.
  8. Khalil S, Bardawil T, Stephan C, Darwiche N, Abbas O, Kibbi A, et al. Retinoids: a journey from the molecular structures and mechanisms of action to clinical uses in dermatology and adverse effects. J Dermatolog Treat. 2017;28(8):684-96.
  9. Finzi AF, Altomare G, Bergamaschini L, Tucci A. Pity- riasis rubra pilaris and retinol-binding protein. Br J Dermatol. 1981;104(3):253-6.
  10. Kanerva L, Lauharanta J, Niemi KM, Lassus A. Ultrastructure of pityriasis rubra pilaris with observations during retinoid (etretinate) treatment. Br J Dermatol. 1983;108(6):653-63.
  11. Fuchs-Telem D, Sarig O, Van Steensel M, Isakov O, Israeli S, Nousbeck J, et al. Familial pityriasis rubra pilaris is caused by mutations in CARD14. Am J Hum Genet. 2012;91(1):163-70.
  12. Takeichi T, Sugiura K, Nomura T, Sakamoto T, Ogawa Y, Oiso N, et al. Pityriasis rubra pilaris type V as an autoinflammatory disease by CARD14 mutations. JAMA Dermatol. 2017;153(1):66-70.
  13. Danis J, Goblos A, Gal B, Sulak A, Farkas K, Torok D, et al. Nuclear factor κB activation in a type V pityriasis rubra pilaris patient harboring multiple CARD14 variants. Front Immunol. 2018;9:1564. doi: 10.3389/fimmu.2018.01564.
  14. Lepekhova AA. Steroid-resistant acantholytic pemphigus, development and justification of therapy. Dis. Moscow; 2015. (in Russian). Available at: https://rusneb.ru/catalog/000199_000009_005559981/. Access 11 Sept 2020
  15. Sergeev PV, Dukhanin AS, Kushlinsky NE. Comparative analysis of glucocorticoids effects on purinergic receptor in peripheral lymphocytes and bone marrow lymphoblasts. Bulletin of the NN Blokhin Cancer Research Center of the Russian Academy of Medical Sciences. Russian Journal. 1997;8(4):18-24. (in Russian)
  16. Dukhanin AS. Membrane mechanisms of glucocorticosteroids’ pharmacological effects. Dis. Moscow; 2001. (in Russian). Available at: https://rusneb.ru/catalog/000200_000018_RU_NLR_bibl_296927/. Access 11 Sept 2020
  17. Zhang Y, Zhou Y, Ball N, Su M, Xu J, Zheng Z. Type I pityriasis rubra pilaris: upregulation of tumor necrosis factor alpha and response to adalimumab therapy. J Cutan Med Surg. 2010;14(4):185-8.
  18. Feldmeyer L, Mylonas A, Demaria O, Mennella A, Yawalkar N, Laffitte E, et al. Interleukin 23-helper T cell 17 axis as a treatment target for pityriasis rubra pilaris. JAMA Dermatol. 2017;153(4):304-8. doi: 10.1001/jamadermatol.2016.5384.
  19. Jha AK, Lallas A, Sonthalia S, Jhakar D, Udayan UK, Chaudhary R. Differentiation of pityriasis rubra pilaris from plaque psoriasis by dermoscopy. Dermatol Pract Concept. 2018;8(4):299-302.
  20. Price L, Lesesky E. Pityriasis rubra pilaris and severe hype- reosinophilia. Cutis. 2017;100(3):E6-7.
  21. Klein A, Landthaler M, Karrer S. Pityriasis rubra pilaris: a review of diagnosis and treatment. Am J Clin Dermatol. 2010;11(3):157-70.
  22. Zavarina IV. Clinical and morphological characteristics of pity- riasis rubra pilaris in children. Dis. Moscow; 2003. (in Russian). Available at: https://rusneb.ru/catalog/000200_000018_RU_NLR_bibl_499700/. Access 11 Sept 2020
  23. Zaouak A, Chamli A, Koubaa W, Hammami H, Fenniche S. Pityriasis rubra pilaris. Presse Med. 2019;48(6):730-1. doi: 10.1016/j.lpm.2019.05.009.
  24. Kromer C, Sabat R, Celis D, Mössner R. Systemic therapies of pityriasis rubra pilaris: a systematic review. J Dtsch Dermatol Ges. 2019;17(3):243-59.
  25. Goldsmith L, Weinrich A, Shupack J. Pityriasis rubra pilaris response to 13-cis-retinoic acid (isotretinoin). J Am Acad Dermatol. 1982;6(4):710-5.
  26. Dicken C. Isotretinoin treatment of pityriasis rubra pilaris. J Am Acad Dermatol.1987;16(2):297-301.
  27. Gemmeke A, Schonlebe J, Koch A, Wollina U. Pityriasis rubra pilaris – a retrospective single center analysis over eight years. J Dtsch Dermatol Ges. 2010;8(6):439-44.
  28. Amann P, Susic M, Gluder F, Berger H, Krapf W, Loffler H. Alitretinoin (9-cis retinoic acid) is effective against pityriasis rubra pilaris: a retrospective clinical study. Acta Derm Venereol. 2015;95(3):329-31.
  29. Moretta G, De Luca E, Di Stefani A. Management of refractory pityriasis rubra pilaris: challenges and solutions. Clin Cosmet Investig Dermatol. 2017;10:451-7.
  30. Dicken CH. Treatment of classic pityriasis rubra pilaris. J Am Acad Dermatol. 1994;31(6):997-9.
  31. Elango T, Dayalan H, Gnanaraj P, Malligarjunan H, Subramanian S. Impact of methotrexate on oxidative stress and apoptosis markers in psoriatic patients. Clin Exp Med. 2014;14(4):431-7.
  32. Porter D, Shuster S. Epidermal renewal and amino acids in psoriasis and pityriasis rubra pilaris. Arch Dermatol. 1968;98(4):339-43.
  33. Brown J, Perry HO. Pityriasis rubra pilaris. Treatment with folic acid antagonists. Arch Dermatol. 1966;94(5):636-38.
  34. Cutolo M, Sulli A, Pizzorni C, Seriolo B, Straub RH. Anti- inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis. 2001;60(8):729-35.
  35. Koch L, Schoffl C, Aberer W, Massone C. Methotrexate treatment for pityriasis rubra pilaris: A case series and literature review. Acta Dermatol Venereol. 2018;98(5):501-5.
  36. Hunter GA, Forbes IJ. Treatment of pityriasis rubra pilaris with azathioprine. Br J Dermatol. 1972;87(1):42-5.
  37. Schram M, Borgonjen R, Bik C, van der Schroeff J, van Everdingen J, Spuls P; Off-Label Working and Project Group of Dutch Society of Dermatology and Venereology. Off-label use of azathioprine in dermatology: a systematic review. Arch Dermatol. 2011;147(4):474-88. doi: 10.1001/archdermatol.2011.79.
  38. Gupta AK, Ellis CN, Nickoloff BJ, Goldfarb MT, Ho VC, Rocher LL, et al. Oral cyclosporin in the treatment of inflammatory and noninflammatory dermatoses: A clinical and immunopathologic analysis. Arch Dermatol 1990;126(3):339-50.
  39. Usuki K, Sekiyama M, Shimada T, Shimada S, Kanzaki T. Three cases of pityriasis rubra pilaris successfully treated with cyclosporin A. Dermatology. 2000;200(4):324-7.
  40. Rosenbach A, Lowe N. Pityriasis rubra pilaris and cyclosporine. Arch Dermatol. 1993;129(10):1346-8.
  41. Ghazi A, Laso-Dosal F. Cyclosporin A and pityriasis rubra pilaris. Acta Derm Venereol. 1990;70(2):181.
  42. Mayer P, van Voorst Vader PC. Lack of effect of cyclosporin A in pityriasis rubra pilaris. Acta Derm Venereol. 1989;69(3):272.
  43. Muller H, Gattringer C, Zelger B, Hopfl R, Eisendle K. Infliximab monotherapy as first-line treatment for adult-onset pityriasis rubra pilaris: case report and review of the literature on biologic therapy. J Am Acad Dermatol. 2008;59(5):65-70.
  44. Petrof G, Almaani N, Archer C, Griffiths W, Smith C. A syste- matic review of the literature on the treatment of pityriasis rubra pilaris type 1 with TNF-antagonists. J Eur Acad Dermatol Venereol. 2013;27(1):131-5.
  45. Karadag A, Kavala M, Ozlu E, Ozkanlı S, Zindancı İ, Turkoglu Z. Erythrodermic pityriasis rubra pilaris: Dramatic response to infliximab therapy. Indian J Dermatol Venereol Leprol. 2016;82(1):112. doi: 10.4103/0378-6323.157457.
  46. Garcovich S, Di Giampetruzzi A, Antonelli G, Garcovich A, Didona B. Treatment of refractory adult-onset pityriasis rubra pilaris with TNF-alpha antagonists: a case series. J Eur Acad Dermatol Venereol. 2010;24(8):881-4.
  47. Eastham A, Femia A, Qureshi A, Vleugels R. Treatment options for pityriasis rubra pilaris including biologic agents: a retrospective analysis from an academic medical center. JAMA Dermatol. 2014;150(1):92-4.
  48. Schreml S, Zeller V, Babilas P, Karrer S, Landthaler M, Szeimies R. Pityriasis rubra pilaris successfully treated with adalimumab. Clin Exp Dermatol. 2010;35(7):792-3.
  49. Schuster D, Pfister-Wartha A, Bruckner-Tuderman L, Schempp CM. Successful treatment of refractory pityriasis rubra pilaris with Secukinumab. JAMA Dermatol. 2016;152(11):1278-80.
  50. Chapalain V, Beylot-Barry M, Doutre MS, Beylot C. Treatment of pityriasis rubra pilaris: a retrospective study of 14 patients. J Dermatol Treat. 1999;10:113-7.
  51. Neess C, Hinrichs R, Dissemond J, Herrmann G, Poswig A, Servera-Llanras M, et al. Treatment of pruritus by capsaicin in a patient with pityriasis rubra pilaris receiving RE-PUVA therapy. Clin Exp Dermatol. 2000;25(3):209-11.
  52. Iredale H, Meggitt S. Photosensitive pityriasis rubra pilaris. Clin Exp Dermatol. 2006;31(1):36-8.
  53. Van de Kerkhof PC, Steijlen PM. Topical treatment of pityriasis rubra pilaris with calcipotriol. Br J Dermatol. 1994;130(5):675-8.
  54. Fraiture AL, Braham C, Pierard-Franchimont C, Pierard GE. How I treat pityriasis rubra pilaris. Rev Med Liege. 2002;57(6):363-5.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 86501 от 11.12.2023 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80653 от 15.03.2021 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies